Please note: The license is valid for 12 months from the date the report is sent.
Report DetailsCancer treatments – here’s your guide to R&D and sales potentials
Do you want to assess the future of cancer-treating medicines? Visiongain’s new report gives you revenue predictions for that industry from 2014, helping you stay ahead. You find financial data, R&D trends, opportunities and outlooks for therapy.
In that analysis you see forecasted sales to 2024 at overall world market, submarket, product and national level. You also assess emerging trends, technologies, and expected therapies.Events shaping that pharmaceuticals industry – why cancer remains healthcare’s top priority
Discover, then, what the future holds for anti-cancer products. And find how patients can benefit. Read on to explore that industry and see what its future market could be worth.Forecasts to 2024 and other analyses show you sales prospects
Besides revenue forecasting to 2024, you find historical data, growth rates and market shares. You assess quantitative and qualitative analyses, business news, outlooks and developments (R&D). You also gain 128 tables, 145 charts and four interviews.
Is finding data for cancer treatment a challenge? Finding information there just got easier. Our work lets you investigate the most promising and lucrative parts of applied oncology. Avoid missing out. Instead you can stay ahead in knowledge and benefit your influence.
Many opportunities remain for cancer-treating drugs. Now see how you can benefit your research, analyses and decisions for medicines including biological drugs (biologics).And the following sections show how you gain from our new investigation.Outlooks for that world market and its submarkets – where does the money lie?
Along with prediction of overall world market value to 2024, our report shows you individual revenue forecasting of four submarkets at world level:
- Targeted treatments
- Hormone-based agents.
Also our study discusses what stimulates and restrains business. That analysis helps you identify potential and find ways for your company to develop. Assess leading brands too.Forecasts for 25 leading drugs and 23 emerging therapies – see potentials
How will leading drugs perform to 2024 at world level? Our study forecasts individual revenues of the top 25 anti-cancer agents, including these products:
- Velcade.You also discover individual selling potentials of 23 rising and emerging therapies, including these:
There you discover how high sales can go, to 2024, finding drugs and years with highest predicted growth and revenues. You see what’s happening, then, understanding trends, competition, challenges and opportunities. In our study you also find geographical revenue predictions.
Leading national markets – where lie highest revenues and growth?
Developments worldwide expand the cancer drugs market, especially rising demand for medicines in emerging countries. China, India, Russia and Brazil underpin revenue growth.In developed and developing countries, opportunities for pharma companies will occur from 2014. See where and how.
Our analyses show you individual revenue forecasts to 2024 for 11 national markets:
- United States (US)
- Germany, France, United Kingdom (UK), Italy and Spain (the EU5 group)
- Brazil, Russia, India and China (BRIC nations).
There you find potential. Our analyses show sales growth will occur in established pharma markets and in developing countries. In particular, drug launches from 2014 to 2024 will change medical prescribing and the commercial landscape. See what’s possible for R&D.Research and deve
Get Industry Insights. Simply.
- Latest reports & slideshows with insights from top research analysts
- 60 Million searchable statistics with tables, figures & datasets
- More than 25,000 trusted sources